Unlock instant, AI-driven research and patent intelligence for your innovation.

Antibodies against FcRn and use thereof

An antibody and antigen technology, applied in the field of antibodies against FCRN and its application, can solve the problem of not generating or detecting antibodies

Active Publication Date: 2011-08-10
TAKEDA PHARMA CO LTD +1
View PDF51 Cites 30 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, said antibodies have not been generated or tested (WO 02 / 43658)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibodies against FcRn and use thereof
  • Antibodies against FcRn and use thereof
  • Antibodies against FcRn and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0517] Example 1: Cloning of FcRn, FcRn-GPI and β 2 m

[0518] The full-length FcRn cDNA construct used in these examples was originally constructed in Simister's laboratory (Brandeis University, Waltham MA) using pcDNA6 (Invitrogen, Carlsbad, CA) as the plasmid vector (FcRn: pcDNA6). The β2m cDNA construct used in these examples was originally constructed in the Blumberg laboratory (Harvard Medical School, Boston, MA) using pcDNA3 (Invitrogen) as the plasmid vector (β2M: pcDNA3).

[0519] Plasmids were transfected into One Shot TOP10 chemically competent E. coli (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Pick a single colony from each transformation plate, inoculate into 500-1000ml of LB medium and culture overnight in a shaker. Plasmid DNA was purified from these cultures using the Maxi Prep kit (Qiagen, Valencia, CA). The pcDNA6-full-length hFcRn plasmid construct was digested with Nhe1 and Xba1. The pCDNA3.1-β2-M plasmid construct was dige...

Embodiment 2

[0520] Example 2: Immunization of mice with plasmid DNA encoding FcRn

[0521] Balb / c mice were treated with 100 μl of 10 mM cardiotoxin (Calbiochem, San Diego) 5 days prior to plasmid DNA injection. Cardiotoxin treatment serves to elicit an inflammatory response and recruit antigen-presenting cells (eg, dendritic cells) to the injected area, thereby enhancing antigen presentation when the plasmid-encoded protein is expressed.

[0522] 100 μg of full-length or GPI-hFcRn plasmid constructs resuspended in 50 μl PBS were injected into the tibialis anterior muscle of mice. Using hFcRn and β 2 Combination immunized mice of M received 50 μg of hFcRn plasmid in 25 μl PBS and 50 μg of β in 25 μl PBS 2 Dosage of M plasmid. All intramuscular injections were performed under systemic anesthesia using phenobarbital (50 mg / kg, intraperitoneal injection) or ketamine (100 mg / kg) / xylazine (10 mg / kg). On days 21 and 42 after the first immunization, animals were boosted with re-injections of...

Embodiment 3

[0527] Example 3: Antibody titers in mouse sera

[0528] Measurement of anti-hFcRn and anti-β in mouse serum using ELISA 2 M titer. Use 2 μg / ml soluble hFcRn or hβ in ELISA coating buffer (Sigma, St. Louis, MO) 2 M (Sigma, St. Louis, MO) ELISA plates were coated. Plates were incubated at 37°C for 1 hour. Plates were washed twice with PBS+0.05% Tween (PBST). Plates were blocked with 1% fish gelatin in PBS at 37°C. Plates were washed twice with PBST. Serially diluted mouse serum (in PBS) was added (100 μl / well) and incubated at 37° C. for 2 hours. Plates were washed 5 times with PBST. Goat anti-mouse IgG-HRP (Pierce, Rockford, IL) was added to the plate at a dilution of 1 to 10,000 and incubated for 1 hour at room temperature. Plates were washed 5 times with PBST. Tetramethylbenzidine (TMB) solution (KPL, Gaithersburg, MD) was added to the plate for color development. The substrate reaction was stopped after 5 minutes when appropriate color development occurred. Plate...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.

Description

[0001] related application [0002] This application claims the benefit of U.S. Provisional Application No. 61 / 048,152, filed April 25, 2008, and U.S. Provisional Application No. 61 / 048,500, filed April 28, 2008, under 35 U.S.C. § 119(e), which The entire contents are incorporated herein by reference in their entirety. Background technique [0003] The most abundant antibody isotype in serum is IgG and it plays a key role in mediating protection against pathogens and in mediating allergic and inflammatory responses that promote the recruitment of immune system components to tissues, mucosal and skin surfaces (Junghans , Immunologic Research 16(1):29(1997)). Furthermore, it is also a key component of various autoimmune diseases. Under normal conditions, the half-life of IgG in serum is in the range of 5-7 days in mice and 22-23 days in humans, a relatively long period of time compared to the serum half-lives of other plasma proteins. This longer cycle occurs in part because...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28A61P37/00
CPCC07K2317/34C07K2317/565C07K16/283C07K16/28C07K2317/21A61K2039/505G01N33/68C07K2317/56A61P37/00A61K39/395C12N15/09C07K2317/33C07K2317/76C07K2317/92C07K2317/55A61K49/0058A61K49/16A61K51/1027C07K2317/20G01N33/6854G01N2333/70535
Inventor 克里斯托弗·滕霍尔阿鲁穆加姆·穆鲁加南达姆罗伯特·查尔斯·拉德纳克莱夫·伍德艾伦·J·比通蒂詹姆斯·斯泰托凯文·麦克唐奈刘立明珍妮弗·杜蒙阿龙·萨托
Owner TAKEDA PHARMA CO LTD